PAMELA PALMER: Open Payments
NPI 1205298023 · KEARNEY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,346 in 63 payments from 15 companies in 2025. Trend: 2023 $1,034 · 2024 $1,176 · 2025 $1,346
Food & beverage: $1,085Consulting: $150Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $424 |
| Neurocrine BioSciences, Inc. | 18 | $287 |
| Teva Pharmaceuticals USA, Inc. | 7 | $203 |
| Biogen, Inc. | 1 | $150 |
| ARGENX US, INC. | 2 | $46 |
| Vifor Pharma, Inc. | 2 | $36 |
| Fresenius USA Marketing, Inc. | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Genentech USA, Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $20 |
Products named: INGREZZA, QULIPTA, TYSABRI, AUSTEDO XR, UBRELVY, CREON, Veltassa, VELPHORO.
Industry payments across NE — which companies pay providers there.
